Related Experiment Videos
Gene therapy for chronic granulomatous disease
Cecilia N Barese1, W Scott Goebel, Mary C Dinauer
1Herman B Wells Center for Pediatric Research and Depatment of Padiatrics (Hematology/Oncology), James Whitcomb Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Expert Opinion on Biological Therapy
|September 1, 2004
Summary
Gene therapy offers a promising treatment for Chronic Granulomatous Disease (CGD), a genetic immune disorder. Research focuses on improving gene transfer into stem cells to restore immune function and combat infections.
Area of Science:
- Immunology
- Genetics
- Hematology
Background:
- Chronic Granulomatous Disease (CGD) is a primary immunodeficiency caused by mutations in NADPH oxidase genes.
- CGD leads to severe, recurrent bacterial and fungal infections and inflammatory granulomas.
- Hematopoietic stem cell (HSC) gene replacement is a potential therapeutic strategy for CGD.
Purpose of the Study:
- To evaluate the feasibility of gene therapy for CGD by reconstituting NADPH oxidase activity.
- To assess the potential clinical benefit of correcting oxidase activity in phagocytes.
- To identify strategies for enhancing gene transfer and engraftment of corrected HSCs.
Main Methods:
- Retroviral and lentiviral gene transfer into human CGD marrow and xenograft models.
- Gene transfer studies in CGD knockout mouse models.
- Phase I clinical trials involving unconditioned CGD patients.
Main Results:
- NADPH oxidase activity was reconstituted in vitro and in vivo through gene transfer.
- Gene-corrected neutrophils showed transient expression in Phase I clinical studies.
- Correction of oxidase activity in a small percentage of phagocytes may offer clinical benefit.
Conclusions:
- Gene therapy is a viable approach for treating CGD.
- Further research is needed to improve gene transfer efficiency into HSCs and enhance engraftment.
- Optimizing vector design and conditioning regimens are key areas for advancing CGD gene therapy.